8-K - Totaligent Inc. | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

Totaligent Inc. entered into a Binding Letter of Intent on February 11, 2026, to acquire the team, intellectual property, and related assets of Aetherium Medical in exchange for equity, with a target closing date of March 5, 2026. This acqui-hire transaction is material as it involves the issuance of 10% of the company's outstanding common stock and the formation of a new subsidiary.

Key Takeaways

1Totaligent entered into a Binding Letter of Intent with Aetherium Medical on February 11, 2026.

2The transaction is an acqui-hire where Totaligent will acquire Aetherium's team, business plan, intellectual property, know-how, contacts, and related assets.

3Consideration is equity only: Totaligent will issue an aggregate 10% of its outstanding common stock (or equivalent) to Ivan Klarich and key Aetherium team members in the form of restricted preferred stock.

4The equity is subject to vesting tied to performance milestones, a 15% escrow holdback for 12 months, repurchase rights, and other customary provisions.

5Totaligent will form a new wholly owned subsidiary named Aetherium Medical LLC to hold the assets, and Ivan Klarich will be appointed as its Managing Director.

6The parties target executing definitive agreements and closing the transaction by approximately March 5, 2026, subject to due diligence and other conditions.

Current Report Details

Event Type

Material Agreement

Exhibits Only

Disclosure

Mandatory

Variant

8-K

Items Reported

1.01

Entry into a Material Definitive Agreement. On February 11, 2026, Totaligent, Inc. (the “Company”) entered into a Binding Letter of Intent (the “LOI”) with Aeth

Material Agreement

Source Document

9.01

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 10.1 Binding Letter of Intent, dated February 11, 2026, between Totaligent, Inc. and Aet

Exhibits Only

Transaction Details

Acquisition / Disposition

Target: Aetherium Medical's team, business plan, intellectual property, know-how, contacts, and related assets
Consideration: Equity in Totaligent, Inc. (aggregate 10% of outstanding common stock or equivalent in restricted preferred stock) with no cash consideration at closing
Structure: Acqui-hire; Assets to be contributed to a new wholly owned subsidiary named Aetherium Medical LLC

•Target closing date: March 5, 2026
•Subject to due diligence
•Subject to execution of definitive agreements
•Subject to no material adverse change
•Subject to board approval if required

Material Agreement

Agreement: Binding Letter of Intent
Parties: Totaligent, Inc., Aetherium Medical

•Sets forth principal terms for a proposed acqui-hire transaction
•Contains binding provisions regarding exclusivity, confidentiality, expenses, and governing law
•Remaining provisions are non-binding and reflect intent to proceed in good faith

Exhibits (2)

10.1

BINDING LETTER OF INTENT

8-K

FORM 8-K